Caas Capital Management LP Biomarin Pharmaceutical Inc Transaction History
Caas Capital Management LP
- $836 Million
- Q3 2024
A detailed history of Caas Capital Management LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Caas Capital Management LP holds 4,400 shares of BMRN stock, worth $293,172. This represents 0.03% of its overall portfolio holdings.
Number of Shares
4,400Holding current value
$293,172% of portfolio
0.03%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding BMRN
# of Institutions
637Shares Held
177MCall Options Held
2.01MPut Options Held
1.28M-
Black Rock Inc. New York, NY22.7MShares$1.52 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.3MShares$1.28 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.9MShares$1.26 Billion0.99% of portfolio
-
Dodge & Cox San Francisco, CA13.9MShares$926 Million0.59% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.5MShares$699 Million0.16% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12.4B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...